- Metformin HCL SR
- Pioglitazone HCL
Metformin – Improves insulin sensitivity & secretion with beneficial effect on lipid levels. Increases glucose utilization in liver & adipose tissues
Glimepiride – Highly effective sulphonylurea for improved glycemic control. Devoid of adverse effects on cardiac functions
Pioglitazone – Effectively improves glucose control, reduces insulin resistance in the liver & peripheral tissues. Exerts beneficial effect on the lipid profile
- Improves glycemic parameters
- Decreases insulin resistance & improves p-cell functions
- Lowers both basal & Postprandial plasma glucose
- Decreases mean cholesterol Increases HDL cholesterol
- Improves platelet function
- Controls chronic systemic inflammation
- Antidiabetic/ Sulfonylurea
- Antidiabetic/ Biguanides
- Antidiabetic/ Thiazolidinediones
- Glimepiride stimulates the insulin release from pancreatic β-cells and reduces glucose output from the liver. It also increases insulin sensitivity at peripheral target sites.
- Metformin is a biguanide w/ anti hyperglycaemic effects, lowering both basal and postprandial plasma glucose. It decreases hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis; delays intestinal absorption of glucose; and enhances insulin sensitivity by increasing peripheral glucose uptake and utilisation.
- Pioglitazone is as a potent and highly selective agonist for the peroxisome proliferator activated receptor-γ (PPAR-γ). Activation of these receptors promotes the production of gene products involved in lipid and glucose metabolism. It also improves insulin response to target cells w/o increasing the pancreatic secretion of insulin.
source :- http://www.cimsasia.com